The update marks a change from the FDA's stance on the topic last year.

New research compares peak enhancement timing of a patient-specific post-trigger delay and a fixed delay during CCTA.

Up to one-third or more of patients who experience moderate or severe allergic-like reactions to ICM must have their imaging protocols revised when subsequent exams involving contrast are requested.

The use of synthetic images could reduce the amount of gadolinium-based contrast agents needed for breast MRI examinations, according to new data published this week in Radiology. 

Experts are hopeful that the first-of-its-kind injectable manganese-based macrocyclic agent will offer a suitable alternative to GBCAs, as it can be more efficiently eliminated from the body.

New data out of the University of New Mexico suggest that the imaging agent’s physiologic reach may exceed what was previously believed.

A Feb. 14 announcement from Bracco indicates that the recently FDA-approved, gadolinium-based contrast agent VUEWAY, also known as gadopiclenol, is officially being used for patients undergoing MR imaging.

Not only does the low-volume contrast protocol preserve supplies, it also protects patients who might be vulnerable to adverse reactions and/or side effects from contrast use.